Issues related to development of antiepileptogenic therapies.
about
Epilepsy related to traumatic brain injury.Anti-epileptogenic clinical trial designs in epilepsy: issues and optionsEtiology matters - Genomic DNA Methylation Patterns in Three Rat Models of Acquired Epilepsy.Epilepsy therapy development: technical and methodologic issues in studies with animal modelsSearching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategiesMicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy--comparison with human epileptic samples.Identification of brain regions predicting epileptogenesis by serial [18F]GE-180 positron emission tomography imaging of neuroinflammation in a rat model of temporal lobe epilepsyAstrocyte-neuronal interactions in epileptogenesis.Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsyContribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.The challenge and promise of anti-epileptic therapy development in animal models.Staged anticonvulsant screening for chronic epilepsy.Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy.Disease modification in epilepsy: from animal models to clinical applications.Epileptogenesis.Optogenetics enlightens neuroscience drug discovery.Circadian clustering of spontaneous epileptic seizures emerges after pilocarpine-induced status epilepticus.Involvement of microRNAs in epileptogenesis.Identifying new antiepileptic drugs through genomics-based drug repurposing.Isoflurane prevents acquired epilepsy in rat models of temporal lobe epilepsy.Altered sensory processing and dendritic remodeling in hyperexcitable visual cortical networks.Molecular imaging reveals epileptogenic Ca2+-channel promoter activation in hippocampi of living mice.Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Isolation and chemical characterization of agelaiatoxin8 (AvTx8) from Agelaia vicina wasp venom and its biological effects on GABA neurotransmission.Epileptogenesis in neonatal brain.Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy.Hypothermia Reduces Mortality, Prevents the Calcium Plateau, and Is Neuroprotective Following Status Epilepticus in Rats.Glial responses during epileptogenesis in Mus musculus point to potential therapeutic targets
P2860
Q27013517-C06BEE7F-F6E2-4BEB-8445-4F1984F169C2Q27027689-00D7D00A-4935-4C1D-9C4F-842FF47F05EAQ27316575-0547FB42-3A4C-4F1B-9E72-74D0084103C1Q30543230-72B74E7C-CBB5-425A-B41D-72BBBE143806Q30576762-F0D01DC5-B633-4EE9-9AB9-537943C01EA3Q30665824-B9B857F5-DEE5-48A3-998B-5E133BAE774DQ30846878-DD82C511-DB68-4DA0-AFED-18CE408E485BQ30911884-F29AA204-B948-43C5-95DB-7777CC2BA1D6Q35693028-B10B761C-FB25-4E64-927B-FFB2D0ADDF78Q36380440-1DFB4A26-2A49-4DFC-B6B1-34BB69F8CCADQ37021058-3A0EA4B5-BB1C-47C6-90A8-9D09362FEE2AQ37214420-1A323D6A-EAEB-4E75-84BB-552CCB15460DQ37577880-5E95EAF6-3F31-40B5-BFCB-81CB391B35DEQ37718027-3851930A-B706-44DE-9E3F-F8D555636E75Q38450069-32E18CC9-4AC0-48B9-BADF-6875B45FC1B4Q38589210-5BC4C293-AC51-4DF3-A144-48F657FECDCBQ38650124-F3816871-4EC6-4991-B6C3-D248F1C4A254Q38679173-AC26DBC5-7DEB-4246-A5D8-B85E76A88F68Q38840417-8D8CC2A8-5051-4526-B048-28E497332D5CQ39040011-BA94DC9F-879F-4552-B35F-344BE6F6FAEBQ40497360-8285C4D2-6441-433A-8CFE-EBF069EC4359Q40748764-DEA4EFA4-BBD4-426C-94C9-035152B4BCDFQ42215148-9A881E83-DEB6-4470-9C80-74FFBB26E1F7Q47653416-0AF8F81A-8F6F-4073-A63C-2808603F35C5Q48266139-656774FD-00F4-456C-B19E-3EB6DC0D796AQ50422432-940F54C7-E125-46F8-840F-6307424AA379Q51818804-94390FB5-7374-452E-8B88-AE66474F4CCDQ55256155-6F200FC3-13CB-470E-AF4B-B2D26E29FE68Q58775273-2BE96F30-F55C-4E4C-A023-FBE81C7FF4AC
P2860
Issues related to development of antiepileptogenic therapies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Issues related to development of antiepileptogenic therapies
@nl
Issues related to development of antiepileptogenic therapies.
@ast
Issues related to development of antiepileptogenic therapies.
@en
type
label
Issues related to development of antiepileptogenic therapies
@nl
Issues related to development of antiepileptogenic therapies.
@ast
Issues related to development of antiepileptogenic therapies.
@en
prefLabel
Issues related to development of antiepileptogenic therapies
@nl
Issues related to development of antiepileptogenic therapies.
@ast
Issues related to development of antiepileptogenic therapies.
@en
P2093
P2860
P3181
P356
P1433
P1476
Issues related to development of antiepileptogenic therapies.
@en
P2093
Amy R Brooks-Kayal
Aristea S Galanopoulou
Asla Pitkänen
Astrid Nehlig
Daniel Friedman
Dieter Schmidt
F Edward Dudek
Frances E Jensen
Henrik Klitgaard
Istvan Mody
P2860
P3181
P356
10.1111/EPI.12297
P407
P478
54 Suppl 4
P577
2013-08-01T00:00:00Z